Peters M, et al. - By performing two surveys, 18 months apart, researchers explored shifts in EGFR (epidermal growth factor receptor) mutation testing as well as treatment practices in non–small-cell lung cancer, given guidelines advise testing for EGFR mutation at diagnosis of advanced non–small-cell lung cancer to guide treatment. The first survey was performed with 562 physicians from Canada, France, Germany, Italy, Japan, South Korea, Spain, Taiwan, the United Kingdom, and the United States. The second one included 707 physicians in the same countries with the addition of China; China was eliminated from year-on-year comparisons. Findings revealed improvements in the availability of test outcomes prior to first-line treatment, but guidelines implementation was incomplete, which is leading to nonreceipt of tyrosine kinase inhibitor therapy on the basis of mutation status in a large proportion of patients. Tumor histology, insufficient tissue, poor performance status, and long test turnaround time were reported as the reasons for not testing; these reasons continued to be the same, year-on-year. It is mandatory to address receiving timely results if treatment parity for eligible patients can be attained. The pivotal steps to improve results are physician education and closer guideline concordance.